meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - 2nd line (L2)
2
sarcomas
thyroid cancer
urothelial cancer (UC) - bladder cancer (BC)
antibody–drug conjugate
enfortumab vedotin-ejfv
sacituzumab govitecan
gene alteration target therapy
FGFR (2/3) gene alteration targeted therapy
erdafitinib
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus SoC
avelumab based treatment
avelumab alone
durvalumab based treatment
durvalumab alone
durvalumab plus BCG
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus BCG
pembrolizumab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
poly ADP-ribose polymerase (PARP) inhibitor
olaparib
no study with result for this clinical condition